Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)

Next Previous
X
Search
Trial Profile

A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BH-200 (Primary)
  • Indications Major depressive disorder
  • Focus Proof of concept; Therapeutic Use
  • Acronyms OLIVE
  • Sponsors HMNC Brain Health

    • Most Recent Events

    • 11 Dec 2024 According to a HMNC Brain Health media release, the company has collaborated in a consortium of respected universities and institutions to win a 4.5m euros grant from the Austrian Research Promotion Agency (FFG). The consortium, which includes the Austrian Institute of Technology and the Danube Private University and others, will receive the funding over three years. This grant will be used for getting new analyses form this trial.
    • 20 Jun 2023 According to a MNC Brain Health media release, company announced that first patient has been enrolled.
    • 30 Mar 2023 Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top